Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it.

Wang W, Vassell R, Song HS, Chen Q, Keller PW, Verma S, Alvarado-Facundo E, Wan H, Schmeisser F, Meseda CA, Weir JP, Weiss CD.

PLoS One. 2019 Sep 12;14(9):e0222436. doi: 10.1371/journal.pone.0222436. eCollection 2019.


Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.

Meseda CA, Atukorale V, Soto J, Eichelberger MC, Gao J, Wang W, Weiss CD, Weir JP.

Sci Rep. 2018 Mar 29;8(1):5364. doi: 10.1038/s41598-018-23712-9.


Development of an animal model of progressive vaccinia in nu/nu mice and the use of bioluminescence imaging for assessment of the efficacy of monoclonal antibodies against vaccinial B5 and L1 proteins.

Zaitseva M, Thomas A, Meseda CA, Cheung CYK, Diaz CG, Xiang Y, Crotty S, Golding H.

Antiviral Res. 2017 Aug;144:8-20. doi: 10.1016/j.antiviral.2017.05.002. Epub 2017 May 8.


Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.

Meseda CA, Atukorale V, Kuhn J, Schmeisser F, Weir JP.

PLoS One. 2016 Feb 19;11(2):e0149364. doi: 10.1371/journal.pone.0149364. eCollection 2016.


Non-coding RNAs and heme oxygenase-1 in vaccinia virus infection.

Meseda CA, Srinivasan K, Wise J, Catalano J, Yamada KM, Dhawan S.

Biochem Biophys Res Commun. 2014 Nov 7;454(1):84-8. doi: 10.1016/j.bbrc.2014.10.035. Epub 2014 Oct 18.


Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus.

Meseda CA, Kuhn J, Atukorale V, Campbell J, Weir JP.

Clin Vaccine Immunol. 2014 Sep;21(9):1330-8. doi: 10.1128/CVI.00347-14. Epub 2014 Jul 16.


Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.

Meseda CA, Campbell J, Kumar A, Garcia AD, Merchlinsky M, Weir JP.

PLoS One. 2013 Jun 13;8(6):e67984. doi: 10.1371/journal.pone.0067984. Print 2013.


Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs.

Zaitseva M, Kapnick SM, Meseda CA, Shotwell E, King LR, Manischewitz J, Scott J, Kodihalli S, Merchlinsky M, Nielsen H, Lantto J, Weir JP, Golding H.

J Virol. 2011 Sep;85(17):9147-58. doi: 10.1128/JVI.00121-11. Epub 2011 Jun 29.


Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.

Meseda CA, Weir JP.

Future Microbiol. 2010 Sep;5(9):1367-82. doi: 10.2217/fmb.10.98. Review.


Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.

He Y, Meseda CA, Vassell RA, Merchlinsky M, Weir JP, Weiss CD.

Vaccine. 2010 Jan 8;28(3):699-706. doi: 10.1016/j.vaccine.2009.10.078. Epub 2009 Nov 1.


Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Meseda CA, Mayer AE, Kumar A, Garcia AD, Campbell J, Listrani P, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2009 Sep;16(9):1261-71. doi: 10.1128/CVI.00040-09. Epub 2009 Jul 15.


Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein.

Adamo JE, Meseda CA, Weir JP, Merchlinsky MJ.

J Gen Virol. 2009 Nov;90(Pt 11):2604-8. doi: 10.1099/vir.0.008474-0. Epub 2009 Jul 8.


Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.

He Y, Manischewitz J, Meseda CA, Merchlinsky M, Vassell RA, Sirota L, Berkower I, Golding H, Weiss CD.

J Infect Dis. 2007 Oct 1;196(7):1026-32. Epub 2007 Aug 20.


Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.

García AD, Meseda CA, Mayer AE, Kumar A, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2007 Aug;14(8):1032-44. Epub 2007 Jun 27.


Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.

Laassri M, Meseda CA, Williams O, Merchlinsky M, Weir JP, Chumakov K.

J Med Virol. 2007 Jun;79(6):791-802.


Vaccinia virus nicking-joining enzyme is encoded by K4L (VACWR035).

Eckert D, Williams O, Meseda CA, Merchlinsky M.

J Virol. 2005 Dec;79(24):15084-90.


Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.

Jones-Trower A, Garcia A, Meseda CA, He Y, Weiss C, Kumar A, Weir JP, Merchlinsky M.

Virology. 2005 Dec 5;343(1):128-40. Epub 2005 Sep 13.


Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.


DNA immunization with a herpes simplex virus 2 bacterial artificial chromosome.

Meseda CA, Schmeisser F, Pedersen R, Woerner A, Weir JP.

Virology. 2004 Jan 5;318(1):420-8.


Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor.

Koelle DM, Liu Z, McClurkan CL, Cevallos RC, Vieira J, Hosken NA, Meseda CA, Snow DC, Wald A, Corey L.

Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12899-904. Epub 2003 Oct 17.


Comparative analysis of the expression of the Epstein-Barr virus (EBV) anti-apoptotic gene BHRF1 in nasopharyngeal carcinoma and EBV-related lymphoid diseases.

Nicholls J, Kremmer E, Meseda CA, Mackett M, Hahn P, Gulley ML, Brink A, Swinnen LJ, Greenspan J, De Souza Y, Grässer F, Sham J, Ng MH, Arrand JR.

J Med Virol. 2001 Sep;65(1):105-13.


Herpesvirus papio encodes a functional homologue of the Epstein-Barr virus apoptosis suppressor, BHRF1.

Meseda CA, Arrand JR, Mackett M.

J Gen Virol. 2000 Jul;81(Pt 7):1801-5.


BHRF1, a viral homologue of the Bcl-2 oncogene, is conserved at both the sequence and functional level in different Epstein-Barr virus isolates.

Khanim F, Dawson C, Meseda CA, Dawson J, Mackett M, Young LS.

J Gen Virol. 1997 Nov;78 ( Pt 11):2987-99.


Supplemental Content

Loading ...
Support Center